These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16861620)

  • 1. Conditional expression of human acid beta-glucosidase improves the visceral phenotype in a Gaucher disease mouse model.
    Sun Y; Quinn B; Xu YH; Leonova T; Witte DP; Grabowski GA
    J Lipid Res; 2006 Oct; 47(10):2161-70. PubMed ID: 16861620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants.
    Sun Y; Quinn B; Witte DP; Grabowski GA
    J Lipid Res; 2005 Oct; 46(10):2102-13. PubMed ID: 16061944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.
    Sun Y; Liou B; Xu YH; Quinn B; Zhang W; Hamler R; Setchell KD; Grabowski GA
    J Biol Chem; 2012 Feb; 287(6):4275-87. PubMed ID: 22167193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.
    Sun Y; Liou B; Ran H; Skelton MR; Williams MT; Vorhees CV; Kitatani K; Hannun YA; Witte DP; Xu YH; Grabowski GA
    Hum Mol Genet; 2010 Mar; 19(6):1088-97. PubMed ID: 20047948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease.
    Schiffer V; Santiago-Mujika E; Flunkert S; Schmidt S; Farcher M; Loeffler T; Schilcher I; Posch M; Neddens J; Sun Y; Kehr J; Hutter-Paier B
    PLoS One; 2020; 15(1):e0227077. PubMed ID: 31929594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.
    McEachern KA; Nietupski JB; Chuang WL; Armentano D; Johnson J; Hutto E; Grabowski GA; Cheng SH; Marshall J
    J Gene Med; 2006 Jun; 8(6):719-29. PubMed ID: 16528760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease.
    Sun Y; Zhang W; Xu YH; Quinn B; Dasgupta N; Liou B; Setchell KD; Grabowski GA
    PLoS One; 2013; 8(3):e57560. PubMed ID: 23520473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.
    Xu YH; Quinn B; Witte D; Grabowski GA
    Am J Pathol; 2003 Nov; 163(5):2093-101. PubMed ID: 14578207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of acid β-glucosidase mutation and Saposin C deficiency in mice reveals Gba1 mutation dependent and tissue-specific disease phenotype.
    Liou B; Zhang W; Fannin V; Quinn B; Ran H; Xu K; Setchell KDR; Witte D; Grabowski GA; Sun Y
    Sci Rep; 2019 Apr; 9(1):5571. PubMed ID: 30944381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models.
    Xu YH; Sun Y; Ran H; Quinn B; Witte D; Grabowski GA
    Mol Genet Metab; 2011 Apr; 102(4):436-47. PubMed ID: 21257328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
    Barnes S; Xu YH; Zhang W; Liou B; Setchell KD; Bao L; Grabowski GA; Sun Y
    PLoS One; 2014; 9(12):e116023. PubMed ID: 25551612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels.
    Xu YH; Reboulet R; Quinn B; Huelsken J; Witte D; Grabowski GA
    Mol Genet Metab; 2008 Jun; 94(2):190-203. PubMed ID: 18346921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease.
    Sanders A; Hemmelgarn H; Melrose HL; Hein L; Fuller M; Clarke LA
    Blood Cells Mol Dis; 2013 Aug; 51(2):109-15. PubMed ID: 23642305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient Expression of Functional Glucocerebrosidase for Treatment of Gaucher's Disease in the Goat Mammary Gland.
    Tavares KC; Dias AC; Lazzarotto CR; Gaudencio Neto S; de Sá Carneiro I; Ongaratto FL; Pinto AF; de Aguiar LH; Calderón CE; Toledo JR; Castro FO; Santos DS; Chies JM; Bertolini M; Bertolini LR
    Mol Biotechnol; 2016 Jan; 58(1):47-55. PubMed ID: 26589705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse.
    Sun Y; Ran H; Liou B; Quinn B; Zamzow M; Zhang W; Bielawski J; Kitatani K; Setchell KD; Hannun YA; Grabowski GA
    PLoS One; 2011 Apr; 6(4):e19037. PubMed ID: 21533102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.
    Sun Y; Liou B; Quinn B; Ran H; Xu YH; Grabowski GA
    PLoS One; 2009 Oct; 4(10):e7320. PubMed ID: 19809509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse.
    Sun Y; Ran H; Zamzow M; Kitatani K; Skelton MR; Williams MT; Vorhees CV; Witte DP; Hannun YA; Grabowski GA
    Hum Mol Genet; 2010 Feb; 19(4):634-47. PubMed ID: 20015957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of dairy goat embryos, by nuclear transfer, transgenic for human acid beta-glucosidase.
    Zhang YL; Wan YJ; Wang ZY; Xu D; Pang XS; Meng L; Wang LH; Zhong BS; Wang F
    Theriogenology; 2010 Mar; 73(5):681-90. PubMed ID: 20053430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher disease.
    Peng Y; Liou B; Inskeep V; Blackwood R; Mayhew CN; Grabowski GA; Sun Y
    Hum Mol Genet; 2019 Oct; 28(20):3406-3421. PubMed ID: 31373366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
    Pandey MK; Burrow TA; Rani R; Martin LJ; Witte D; Setchell KD; Mckay MA; Magnusen AF; Zhang W; Liou B; Köhl J; Grabowski GA
    Nature; 2017 Mar; 543(7643):108-112. PubMed ID: 28225753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.